Study of BMS-986158 in Subjects With Select Advanced Cancers

Part of paid clinical trials in Duarte, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02419417
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Advanced Tumors

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986158 — DRUG
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers

Key Dates

Start date
Jun 19, 2015
Status verified
May 2022
Primary completion
Mar 17, 2021
Completion
Mar 17, 2021

Study Design

Enrollment
83 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Monotherapy Treatment
    Patients treated at various doses and schedules
  • Experimental: Combination Therapy
    Patients treated at selected doses and schdules

Primary Outcome Measure

Number of Participants Experiencing Adverse Events [ Time Frame: From first dose to 30 days following last dose (up to approximately 29 months) ]

Locations (6)

FacilityCityStateZIPSite coordinators
City Of Hope National Medical CenterDuarteCalifornia91010-
University Of ColoradoAuroraColorado80045-
Dana Farber Cancer Institute.BostonMassachusetts02215-
Oregon Health & Science UniversityPortlandOregon97239-
Univ. Of PaPhiladelphiaPennsylvania19104-
Institute for Translational Oncology Research-ITORGreenvilleSouth Carolina29605-

Find similar trials in Duarte, CA

By research site
City Of Hope National Medical Center· Duarte, CAUniversity Of Colorado· Aurora, CODana Farber Cancer Institute.· Boston, MAOregon Health & Science University· Portland, ORUniv. Of Pa· Philadelphia, PAInstitute for Translational Oncology Research-ITOR· Greenville, SC

Related Studies